Insight into the metabolic shifts in Graves' hyperthyroidism: a study of acylcarnitine and lipid profiles
Authors' conclusion
Increased levels of medium- and long-chain acylcarnitines in patients with newly diagnosed Graves' disease may reflect accelerated catabolism. Lower levels of short-chain acylcarnitines point to Graves' disease being a catabolic condition, with a shift in energy source from carbohydrates to fat.
Study context
- Population
- Newly diagnosed Graves' disease patients (100 main cohort, 51 validation) and age- and sex-matched healthy subjects100 + 51 validation
- Comparison
- Newly diagnosed GD patients vs healthy subjects
- Hyperthyroid GDn = 88
- Outcome
- Acylcarnitine profiles (23 acylcarnitines)
Methodological detailsage- and sex-matched healthy controls, validation cohort
- Age- and sex-matched healthy controls
- Validation cohort
Main finding
As reported in the abstract
- Significantly (P < 0.05) higher medium- and long-chain acylcarnitines and lower short-chain acylcarnitines in hyperthyroid GD vs healthy subjects
- Factor analysis: medium- and long-chain acylcarnitines explained most of the differences between groups
Observational data: associations, not effects.
Further findings
Lipids/apolipoproteins
- Serum levels of five lipids/apolipoproteins significantly lower in hyperthyroid GD vs healthy subjects
Acylcarnitines after antithyroid drugs · 6 weeks
- Patients treated with antithyroid drugs for 6 weeks (n = 21) had acylcarnitine levels closer to healthy subjects vs 79 treatment-naïve hyperthyroid patients
Validation group
- Main findings confirmed in the validation group
Original publication
Insight into the metabolic shifts in Graves' hyperthyroidism: a study of acylcarnitine and lipid profiles. Eur Thyroid J. Published 28 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →